Hepatitis Treatment Market By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Others), By Drug Type (Vaccines, Anti-Viral Drugs, Interferons, Others), By Route of Administration (Oral , Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography.  

Purchase Option

$ 4400
$ 6600
$ 8900

Hepatitis Treatment Market size was valued at USD 4.2 Billion in 2022 and expected to reach USD 6.4 Billion by 2029, at a CAGR of 5.7% from 2023-2029. Hepatitis is the disease characterized by the inflammation of the liver. Hepatitis mainly occur due to the viral infections, heavy alcohol intake, consumption of hepatotoxic drugs, blood transfusions and autoimmune diseases among others. Hepatitis is classified as hepatitis A, B, C, D, E in which hepatitis A, B, C mostly occurs in humans. The symptoms associated with hepatitis include poor appetite, whites of eyes, discoloration of skin, vomiting, abdominal pain, and diarrhoea among others. Hepatitis can be prevented by the administration of vaccines in newborn babies. Increase in the incidence of different types of hepatitis infections, the rise in R&D activities for the development of newer drugs and vaccines, government initiations for the prevention of hepatitis, promising pipeline products for the hepatitis treatment are anticipated to fuel the hepatitis treatment market over the forecast period. Moreover, the rise in awareness about hepatitis treatment options among key stakeholders, increase in the consumption of alcohol, and high usage of hepatotoxic drugs and other toxins are expected to propel the hepatitis treatment market over the forecast period. However, stringent regulatory policies for the product approval, lack of vaccines for certain types hepatitis such as hepatitis C, and the high cost of the treatment are expected to hinder the growth of hepatitis treatment market over the forecast period.

 

Hepatitis Treatment Market Key Developments:
  • For instance, in June 2016, FDA approved Epclusa manufactured by Gilead Sciences, Inc. used in the treatment of chronic hepatitis C virus infection.
  • In September 2017, China Food and Drug Administration approved Gileads Sovaldi (Sofosbuvir) used in the treatment of chronic HCV infection.
  • In May 2017, Eiger Biopharmaceuticals filed investigational new drug application with FDA for Lambda (pegylated interferon lambda 1a) for the treatment of hepatitis D.

Hepatitis Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.7%

Largest Market

North America

Fastest Growing Market

Europe
Hepatitis Treatment Market Dynamics

hepatitis treatment market is driven by rising in the prevalence of various types of hepatitis infections. According to WHO in 2015, approximately 257 Mn hepatitis B, 71 Mn hepatitis C cases, and approximately 15 Mn hepatitis D cases observed around the globe. Majority of the local and international market players are actively seeking to develop newer drugs and vaccines for the treatment of hepatitis infection. Moreover, strong product pipeline for hepatitis treatment expected to upsurge the market revenue over the forecast timeframe. Furthermore, acquisitions and mergers, product approvals, and product launchings are the strategies adopted by the market players for dominating the hepatitis treatment market. 

Hepatitis Treatment Market Segmentation

By Disease Type
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
  • Hepatitis E
  • Others
By Drug Type
  • Vaccines
  • Anti-Viral Drugs
  • Interferons
  • Others
By Route Administration
  • Oral
  • Parenteral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Frequently Asked Questions

The hepatitis treatment market is projected to expand at a CAGR of 5.7% during the forecast period

Hoffmann- La Roche Ltd, Gilead Sciences, Novartis AG, Bristol-Myers Squibb, GlaxoSmithKline, plc.

Europe is the fastest-growing region for hepatitis treatment market

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Hepatitis Treatment Market Introduction 
2.1.Global Hepatitis Treatment Market  - Taxonomy
2.2.Global Hepatitis Treatment Market  - Definitions
2.2.1.Disease Type 
2.2.2.Drug Type
2.2.3.Route of Administration
2.2.4.Distribution Channel
2.2.5.Region
3.Global Hepatitis Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Hepatitis Treatment Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Hepatitis Treatment Market  By Disease Type , 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Hepatitis A
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Hepatitis B
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Hepatitis C
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Hepatitis D
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Hepatitis E
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Others
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
6.Global Hepatitis Treatment Market  By Drug Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Vaccines
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Anti-Viral Drugs
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Interferons
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Others
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Hepatitis Treatment Market  By Route of Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Oral
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Parenteral
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Hepatitis Treatment Market  By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Online Pharmacies
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Hepatitis Treatment Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Hepatitis Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Disease Type  Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Hepatitis A
10.1.2.Hepatitis B
10.1.3.Hepatitis C
10.1.4.Hepatitis D
10.1.5.Hepatitis E
10.1.6.Others
10.2.  Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Vaccines
10.2.2.Anti-Viral Drugs
10.2.3.Interferons
10.2.4.Others
10.3.  Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Oral
10.3.2.Parenteral
10.4.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital Pharmacies
10.4.2.Retail Pharmacies
10.4.3.Online Pharmacies
10.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Hepatitis Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Disease Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Hepatitis A
11.1.2.Hepatitis B
11.1.3.Hepatitis C
11.1.4.Hepatitis D
11.1.5.Hepatitis E
11.1.6.Others
11.2.  Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Vaccines
11.2.2.Anti-Viral Drugs
11.2.3.Interferons
11.2.4.Others
11.3.  Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Oral
11.3.2.Parenteral
11.4.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital Pharmacies
11.4.2.Retail Pharmacies
11.4.3.Online Pharmacies
11.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
11.5.7.
12.Asia Pacific (APAC) Hepatitis Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Disease Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Hepatitis A
12.1.2.Hepatitis B
12.1.3.Hepatitis C
12.1.4.Hepatitis D
12.1.5.Hepatitis E
12.1.6.Others
12.2.  Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Vaccines
12.2.2.Anti-Viral Drugs
12.2.3.Interferons
12.2.4.Others
12.3.  Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Oral
12.3.2.Parenteral
12.4.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital Pharmacies
12.4.2.Retail Pharmacies
12.4.3.Online Pharmacies
12.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Hepatitis Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Disease Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Hepatitis A
13.1.2.Hepatitis B
13.1.3.Hepatitis C
13.1.4.Hepatitis D
13.1.5.Hepatitis E
13.1.6.Others
13.2.  Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Vaccines
13.2.2.Anti-Viral Drugs
13.2.3.Interferons
13.2.4.Others
13.3.  Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Oral
13.3.2.Parenteral
13.4.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital Pharmacies
13.4.2.Retail Pharmacies
13.4.3.Online Pharmacies
13.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Hepatitis Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
14.1. Disease Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Hepatitis A
14.1.2.Hepatitis B
14.1.3.Hepatitis C
14.1.4.Hepatitis D
14.1.5.Hepatitis E
14.1.6.Others
14.2.  Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Vaccines
14.2.2.Anti-Viral Drugs
14.2.3.Interferons
14.2.4.Others
14.3.  Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Oral
14.3.2.Parenteral
14.4.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital Pharmacies
14.4.2.Retail Pharmacies
14.4.3.Online Pharmacies
14.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Hoffmann- La Roche Ltd. (Switzerland)
15.2.2.Gilead Sciences (U.S.)
15.2.3.Novartis AG (Switzerland)
15.2.4.Bristol-Myers Squibb (U.S)
15.2.5.GlaxoSmithKline, plc.
15.2.7.Merck and Co, Inc. (U.S)
15.2.8.Johnson & Johnson Services, Inc. (U.S.)
15.2.9.AbbVie Inc. (U.S.)
15.2.10.Novira Therapeutics Inc. (U.S.)
15.2.11.Eiger Biopharmaceuticals (U.S.)
16. Research Methodology 
17. Appendix and Abbreviations 
  • Hoffmann- La Roche Ltd. (Switzerland)
  • Gilead Sciences (U.S.)
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb (U.S)
  • GlaxoSmithKline, plc.
  • Merck and Co, Inc. (U.S)
  • Johnson & Johnson Services, Inc. (U.S.)
  • AbbVie Inc. (U.S.)
  • Novira Therapeutics Inc. (U.S.)
  • Eiger Biopharmaceuticals (U.S.)

Adjacent Markets